- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Amicus Therapeutics Inc (FOLD)
Assess today's live Amicus Therapeutics Inc (FOLD) share price, performance and insights using our live NASDAQ: FOLD stock exchange data.
Analyse the historical data and Amicus Therapeutics Inc share price performance charts on this page. Our technical summary section provides analysis on Amicus share price buy/sell indicators using real-time data (or discuss the Amicus (FOLD) stock price today with other investors in the Amicus NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ FOLD share price (ISIN: US03152W1099) to enhance your trading decisions with our free investment tools and resources.
What Is the Amicus Therapeutics Inc Share Price Today?
The Amicus share price today is 14.210.
What Is the Stock Symbol for Amicus Therapeutics Inc
The stock symbol (or 'ticker') for Amicus Therapeutics Inc is "FOLD."
What Stock Exchange Does Amicus Therapeutics Inc Trade On?
Amicus Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Amicus Therapeutics Inc a Good Stock to Buy?
Determining whether Amicus Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Amicus Therapeutics Inc share price performance charts on this page. Our technical summary section provides analysis on Amicus share price buy/sell indicators using real-time data (or discuss the Amicus (FOLD) stock price today with other investors in the Amicus NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ FOLD share price (ISIN: US03152W1099) to enhance your trading decisions with our free investment tools and resources.
What Is the Amicus Therapeutics Inc Share Price Today?
The Amicus share price today is 14.210.
What Is the Stock Symbol for Amicus Therapeutics Inc
The stock symbol (or 'ticker') for Amicus Therapeutics Inc is "FOLD."
What Stock Exchange Does Amicus Therapeutics Inc Trade On?
Amicus Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Amicus Therapeutics Inc a Good Stock to Buy?
Determining whether Amicus Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.180
14.220
52 wk Range
5.510
14.360
Unusual trading volume
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.18014.220
52 wk Range
5.51014.360
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
FOLD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
15.250
Upside
+7.32%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Amicus Company Profile
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Amicus Therapeutics Inc Earnings Call Summary for Q3/2025
- Amicus Therapeutics exceeded Q3 2025 expectations with EPS of $0.06 (100% above forecast) and revenue of $169.1 million (19% YoY growth), resulting in a 1.02% pre-market stock increase.
- The company reported its first quarter of GAAP net income at $17.3 million and non-GAAP net income of $54.2 million, with cash reserves increasing by $32.8 million to $263.8 million.
- Strong performance was driven by Galafold (12% growth, 69% market share) and Pombiliti/Opfolda (42% revenue surge) with successful international market expansion.
- Management projects 15-22% total revenue growth for 2025, with Galafold growing 10-15% and Pombiliti/Opfolda increasing 50-65%, targeting combined sales of $1 billion by 2028.
- The company is pursuing label expansions for its products while addressing challenges including market competition, regulatory hurdles, and potential supply chain disruptions.
Last Updated: 04/11/2025, 14:54
Read Full TranscriptCompare FOLD to Peers and Sector
Metrics to compare | FOLD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFOLDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −311.8x | −1.8x | −0.6x | |
PEG Ratio | −3.59 | 0.01 | 0.00 | |
Price/Book | 19.0x | 2.7x | 2.6x | |
Price / LTM Sales | 7.3x | 9.5x | 3.2x | |
Upside (Analyst Target) | 3.8% | 130.6% | 41.8% | |
Fair Value Upside | Unlock | 16.6% | 5.1% | Unlock |
Analyst Ratings
3 Buy
4 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 15.250
(+7.32% Upside)
Earnings
Latest Release
Nov 04, 2025
EPS / Forecast
0.06 / 0.03
Revenue / Forecast
169.06M / 165.44M
People Also Watch
FAQ
What Is the Amicus (FOLD) Share Price Today?
The live Amicus share price today is 14.210
What Stock Exchange Does Amicus (FOLD) Trade On?
Amicus is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Amicus?
The stock symbol (also called a 'ticker') for Amicus is "FOLD."
What Is the Current Amicus Market Cap?
As of today, Amicus market capitalisation is 4.39B.
What Is Amicus's (FOLD) Earnings Per Share (TTM)?
The Amicus EPS is currently -0.05 (Trailing Twelve Months).
When Is the Next Amicus Earnings Date?
Amicus's next earnings report will be released on 19 Feb 2026.
Is FOLD a Buy or Sell From a Technical Analyst Perspective?
Based on today's Amicus moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Amicus Stock Split?
Amicus has split 0 times. (See the FOLD stock split history page for full effective split date and price information.)
How Many Employees Does Amicus Have?
Amicus has 499 employees.
What is the current trading status of Amicus (FOLD)?
As of 24 Dec 2025, Amicus (FOLD) is trading at a price of 14.210, with a previous close of 14.210. The stock has fluctuated within a day range of 14.180 to 14.220, while its 52-week range spans from 5.510 to 14.360.
What Is Amicus (FOLD) Price Target According to Analysts?
The average 12-month price target for Amicus is USD15.25, with a high estimate of USD17 and a low estimate of USD14.5. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +7.32% Upside potential.
What Is the FOLD After Hours Price?
FOLD's last after hours stock price is 14.090, the stock has decreased by -0.120, or -0.840%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.